Company intelligence / Profile preview

Scorpius Holdings

Morrisville, North Carolina, United Statesscorpiusbiologics.com ↗

Ownership: Public · NHWK
Development stage: Commercial

Overview

NightHawk Biosciences developed a pipeline focused on immunotherapies for oncology and infectious disease. Notable assets included HS‑110 in Phase 2 for non-small-cell lung cancer and PTX‑35 in Phase 1 for solid tumors. The company also commercialized obiltoxaximab for anthrax exposure. In early 2024 the company rebranded as Scorpius Holdings to focus on large molecule biomanufacturing CDMO services

Therapeutic areas: OncologyPsychiatryInfectious Diseases
Modalities: Monoclonal antibodyVaccineSmall moleculeCell therapyBiologic
Industry: Contract Manufacturing Organization

Partnerships

Kansas State University’s Biosecurity Research Institute—collaboration on RapidVax program

Financials

Market cap: $10.8M
Total revenue: $2.3M
Enterprise value: $12.6T

Beyond the preview

Go deeper on Scorpius Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scorpius Holdings.

Explore the full profile